Faeth Therapeutics Partners With Roche on Breast Cancer Trial
The collaboration pairs Faeth's PIKTOR combination with Roche's giredestrant in a Phase 1b/2 study of advanced breast cancer.
Updated on Nov. 16, 2026 in Cancer

Faeth Therapeutics, a clinical-stage oncology company based in Austin, Texas, has entered a clinical trial collaboration and supply agreement with Roche. Under the deal, Faeth will sponsor and conduct the Phase 1b/2 study FTH-PIK-101, while Roche supplies giredestrant.
Why it matters
The study tests whether blocking the PI3K/AKT/mTOR pathway can overcome resistance to endocrine therapy in HR+/HER2- breast cancer. Faeth retains all rights to its lead program, PIKTOR.
Preliminary topline results from Faeth's Phase 2 endometrial cancer trial were reported on November 9, 2026, with response rates of up to 50% seen in solid tumors with a dysregulated PI3K/AKT/mTOR pathway. Full results and the breast cancer study's efficacy data remain unreported, with interim breast cancer data expected in 2027.
The players
Faeth Therapeutics
Faeth Therapeutics is a clinical-stage oncology company headquartered in Austin, Texas, whose lead program is the investigational PIKTOR combination.
F. Hoffmann-La Roche Ltd
F. Hoffmann-La Roche Ltd is a Swiss multinational pharmaceutical company and a major developer of cancer therapies, supplying giredestrant to the study.
The details
PIKTOR is an investigational all-oral combination of serabelisib, a selective PI3K-alpha inhibitor, and sapanisertib, an mTORC1/mTORC2 inhibitor. The study evaluates PIKTOR alongside endocrine-directed agents, and the first patient was dosed in April 2026.
Timeline
April 2026: First patient dosed in the Phase 1b/2 breast cancer trial.
November 9, 2026: Preliminary topline results reported for the endometrial Phase 2 trial.
November 16, 2026: Collaboration and supply agreement with Roche announced.
2027: Interim data from the breast cancer Phase 1b/2 trial anticipated.
Big Picture
The trial builds on the established finding that PI3K/AKT/mTOR pathway activation drives resistance to endocrine therapy in HR+/HER2- breast cancer, testing whether an all-oral combination can address that resistance. It follows a broader industry pattern of pairing targeted pathway inhibitors with existing endocrine agents to extend treatment benefit.
For patients with HR+/HER2- breast cancer whose disease has stopped responding to endocrine therapy, this trial represents a new investigational option under study rather than an available treatment. Participation would be limited to eligible patients enrolled in the Phase 1b/2 study, and no approval or commercial availability has been announced.
The takeaway
Research into blocking the PI3K/AKT/mTOR pathway may offer a path past endocrine resistance in breast cancer, but results from the breast cancer trial are still pending. Patients and caregivers should discuss emerging trial options with their oncologists.
What happens next
Interim data from the Phase 1b/2 breast cancer trial is anticipated in 2027.
Further reading
Explore more on Cancer developments and clinical research across Texas.
Source note: This article includes information reported by Firstwordpharma.






